Clinical Trial Update: Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating 5 weeks of treatment with BGG492 for muscle spasticity in patients with multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• BGG492

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Muscle Spasticity Due to Multiple Sclerosis | Phase 2 | Status: WITHDRAWN